SMAD4 Antibody, KO Validated | 18-268

SMAD4 Antibody, KO Validated | 18-268 | Gentaur UK, US & Europe Distribution

Host: Rabbit

Reactivity: Human, Mouse

Homology: N/A

Immunogen: Recombinant fusion protein containing a sequence corresponding to amino acids 160-450 of human SMAD4 (NP_005350.1) .

Research Area: Apoptosis, Cancer, Cell Cycle, Signal Transduction, Stem Cell, Transcription

Tested Application: WB, IF

Application: WB: 1:500 - 1:2000
IF: 1:50 - 1:200

Specificiy: N/A

Positive Control 1: HeLa

Positive Control 2: N/A

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: Observed: 60kDa

Validation: Antibody is Knockout validated.

Isoform: N/A

Purification: Affinity purification

Clonality: Polyclonal

Clone: N/A

Isotype: IgG

Conjugate: Unconjugated

Physical State: Liquid

Buffer: PBS with 0.02% sodium azide, 50% glycerol, pH7.3.

Concentration: N/A

Storage Condition: Store at -20˚C. Avoid freeze / thaw cycles.

Alternate Name: SMAD4, JIP, DPC4, MADH4, MYHRS

User Note: Optimal dilutions for each application to be determined by the researcher.

BACKGROUND: This gene encodes a member of the Smad family of signal transduction proteins. Smad proteins are phosphorylated and activated by transmembrane serine-threonine receptor kinases in response to TGF-beta signaling. The product of this gene forms homomeric complexes and heteromeric complexes with other activated Smad proteins, which then accumulate in the nucleus and regulate the transcription of target genes. This protein binds to DNA and recognizes an 8-bp palindromic sequence (GTCTAGAC) called the Smad-binding element (SBE) . The Smad proteins are subject to complex regulation by post-translational modifications. Mutations or deletions in this gene have been shown to result in pancreatic cancer, juvenile polyposis syndrome, and hereditary hemorrhagic telangiectasia syndrome.